<SEC-DOCUMENT>0001628280-22-014881.txt : 20220519
<SEC-HEADER>0001628280-22-014881.hdr.sgml : 20220519
<ACCEPTANCE-DATETIME>20220519162529
ACCESSION NUMBER:		0001628280-22-014881
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20220519
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220519
DATE AS OF CHANGE:		20220519

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ChromaDex Corp.
		CENTRAL INDEX KEY:			0001386570
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				262940963
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37752
		FILM NUMBER:		22943185

	BUSINESS ADDRESS:	
		STREET 1:		10900 WILSHIRE BLVD
		STREET 2:		SUITE 600
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90024
		BUSINESS PHONE:		310-388-6706

	MAIL ADDRESS:	
		STREET 1:		10900 WILSHIRE BLVD
		STREET 2:		SUITE 600
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90024

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CODY RESOURCES, INC.
		DATE OF NAME CHANGE:	20070112
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cdxc-20220519.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:f0c1e2ed-9b8f-4ae5-8f58-6ccc4c4ae049,g:80676cc1-0433-417f-a180-197fa0d0234f,d:3c146dd07c40479c9fef3188ecd3193f--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cdxc-20220519</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl80L2ZyYWc6ZjIwZGNlYmQyZTMyNDVjOTg2MmFmNGZmY2E4MmFkOTUvdGFibGU6YmIxNWM5NzEzYmE2NGYyZGI3ZGFkZDBjYWVjZDFkNDMvdGFibGVyYW5nZTpiYjE1Yzk3MTNiYTY0ZjJkYjdkYWRkMGNhZWNkMWQ0M18wLTItMS0xLTg0NDYz_d78bd379-183a-437f-92b1-9ac74ef9e14b">0001386570</ix:nonNumeric><ix:nonNumeric contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl80L2ZyYWc6ZjIwZGNlYmQyZTMyNDVjOTg2MmFmNGZmY2E4MmFkOTUvdGFibGU6YmIxNWM5NzEzYmE2NGYyZGI3ZGFkZDBjYWVjZDFkNDMvdGFibGVyYW5nZTpiYjE1Yzk3MTNiYTY0ZjJkYjdkYWRkMGNhZWNkMWQ0M18xLTItMS0xLTg0NDYz_b5489db6-c3f7-4b62-a3ca-e5a399162b7c">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cdxc-20220519.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001386570</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-19</xbrli:startDate><xbrli:endDate>2022-05-19</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i3c146dd07c40479c9fef3188ecd3193f_1"></div><div style="min-height:36pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></div><div style="padding-left:122.3pt;padding-right:122.3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-top:1.05pt;padding-left:88.3pt;padding-right:88.3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:0.1pt;padding-left:113.95pt;padding-right:113.95pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:12pt;padding-left:129.37pt;padding-right:129.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8xNjY4_caad9715-cc1c-487f-8110-e1226a812892">8-K</ix:nonNumeric></span></div><div style="margin-top:0.1pt;text-align:center"><span><br/></span></div><div style="padding-left:120.27pt;padding-right:120.27pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:0.1pt;text-align:center"><span><br/></span></div><div style="padding-left:91.05pt;padding-right:91.05pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></div><div style="padding-left:88.8pt;padding-right:88.8pt;text-align:center"><span><br/></span></div><div style="margin-top:0.45pt;padding-left:81.22pt;padding-right:81.22pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8yMjU_076fcca9-7474-4fa8-9614-f8b93f637fea">May 19, 2022</ix:nonNumeric></span></div><div style="margin-top:0.1pt;text-align:center"><span><br/></span></div><div style="padding-left:105.87pt;padding-right:105.87pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8xNjY0_a54e1676-9fd7-4c0d-9196-a82dc518a478">CHROMADEX CORPORATION</ix:nonNumeric></span></div><div style="margin-top:1.05pt;padding-left:90.42pt;padding-right:90.42pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="padding-left:90.42pt;padding-right:90.42pt;text-align:center"><span><br/></span></div><div style="padding-left:90.42pt;padding-right:90.42pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGFibGU6NzA5NGYyOTEyMjhhNGU4OTk5NWU0YzA0MDQ2MTBkZTEvdGFibGVyYW5nZTo3MDk0ZjI5MTIyOGE0ZTg5OTk1ZTRjMDQwNDYxMGRlMV8wLTAtMS0xLTg0NDYz_77bd4dc6-f6e8-4135-a529-24349206d521">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGFibGU6NzA5NGYyOTEyMjhhNGU4OTk5NWU0YzA0MDQ2MTBkZTEvdGFibGVyYW5nZTo3MDk0ZjI5MTIyOGE0ZTg5OTk1ZTRjMDQwNDYxMGRlMV8wLTItMS0xLTg0NDYz_97072ed8-cfad-4697-97a0-8a0b4bdaf4e6">001-37752</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGFibGU6NzA5NGYyOTEyMjhhNGU4OTk5NWU0YzA0MDQ2MTBkZTEvdGFibGVyYW5nZTo3MDk0ZjI5MTIyOGE0ZTg5OTk1ZTRjMDQwNDYxMGRlMV8wLTQtMS0xLTg0NDYz_9d51acba-2b8e-4601-9f40-ce75efb95c70">26-2940963</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="padding-left:90.42pt;padding-right:90.42pt;text-align:center"><span><br/></span></div><div style="margin-top:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8xNjY5_d88a605b-abe6-4d04-872e-3dfeb86a3d63">10900 Wilshire Blvd.</ix:nonNumeric> <ix:nonNumeric contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8xNjY1_d889bd11-9af6-4d65-88fe-bc28d32725be">Suite 600</ix:nonNumeric>, <ix:nonNumeric contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8xNjYw_10834414-e915-41a1-808b-9fb4cb956e38">Los Angeles</ix:nonNumeric>, <ix:nonNumeric contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8xNjY2_f27e171c-e7ef-4409-b5b7-11e228ec9971">California</ix:nonNumeric> <ix:nonNumeric contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8xNjcz_285f3ba4-0930-4f85-900a-387298e93779">90024</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8xNjcw_81bb91c4-294b-4033-bb8f-a0f33dcc5365">(310)</ix:nonNumeric> <ix:nonNumeric contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8xNjYx_13174e0b-6cc4-483b-9309-60ecbadc5f8e">388-6706</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Registrant's telephone number, including area code)</span></div><div style="margin-top:0.25pt"><span><br/></span></div><div style="margin-top:1.95pt;padding-right:24.45pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:0.15pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8xNjYy_fe7736b5-1bad-444a-b371-15f14fe56a42">&#9744;</ix:nonNumeric>    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-top:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8xNjcx_ed4d43f0-6b8d-4da6-8991-8ad8fb0ab34c">&#9744;</ix:nonNumeric>    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-top:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8xNjYz_8ce49bcf-4cbe-4e63-a9d9-b8085fb42972">&#9744;</ix:nonNumeric>    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-top:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8xNjcy_870db41b-65ab-457d-bf4d-912634e0312f">&#9744;</ix:nonNumeric>    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:2pt;padding-right:100.7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="padding-right:100.7pt"><span><br/></span></div><div style="padding-left:50.35pt;padding-right:50.35pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Title of each class</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Trading Symbol(s)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGFibGU6NjEyZDhiYWZjYTc1NDUzZTgzODUwN2UxOWM3YTdmNDkvdGFibGVyYW5nZTo2MTJkOGJhZmNhNzU0NTNlODM4NTA3ZTE5YzdhN2Y0OV8xLTAtMS0xLTg0NDYz_a8b8eea6-428e-4cc2-a452-daa0251f1ed7">Common Stock, par value $0.001 per share</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:30.22pt;padding-right:30.22pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGFibGU6NjEyZDhiYWZjYTc1NDUzZTgzODUwN2UxOWM3YTdmNDkvdGFibGVyYW5nZTo2MTJkOGJhZmNhNzU0NTNlODM4NTA3ZTE5YzdhN2Y0OV8xLTEtMS0xLTg0NDYz_45085de1-b1df-44c7-9f4a-1b040a8eca73">CDXC</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.85pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Nasdaq Capital Market</span></div></td></tr></table></div><div style="margin-top:0.35pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:0.2pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonNumeric contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8xNjY3_92f8e116-c3ad-48f4-85e5-edd40b61eb8d">&#9744;</ix:nonNumeric></span></div><div style="margin-top:0.75pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="padding-left:14pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></div></div><div id="i3c146dd07c40479c9fef3188ecd3193f_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.01 Entry into a Material Definitive Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 19, 2022, ChromaDex Corporation (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) entered into an agreement (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) for the formation of a joint venture (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">JV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) among Crystal Lake Developments Limited (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Crystal Lake</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), Pioneer Idea Holdings Limited (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pioneer Idea</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and Hong Kong Taikuk (China) Group Ltd (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Taikuk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  The purpose of the JV will be to commercialize Tru Niagen&#174; and other products containing nicotinamide riboside to be developed by the Company in the ordinary course (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) in Mainland China and its territories, excluding Hong Kong, Macau and Taiwan (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Territory</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  At the closing of the formation of the JV (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Closing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) the Company will license to the JV certain inventions and trademarks relating to the Products and will exclusively own any invention developed by the JV that incorporates such intellectual property.  The Agreement will have an initial term of 20 years, unless earlier terminated.  The Closing is subject to certain customary closing conditions and is expected by the end of the third quarter of 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Crystal Lake, Pioneer Idea and Taikuk have each agreed to contribute $1.8 million, $1.2 million and $1.0 million, respectively into the JV.  In addition, the Company has agreed to pay $1.0 million to Taikuk and Taikuk will receive an additional 5% non-voting equity interest in the JV for introducing the parties.  Following the closing, each of the parties will hold the following interest in the JV: the Company (71%), Crystal Lake (10.8%), Pioneer Idea (7.2%) and Taikuk (a 11% non-voting interest).  The Company will have the right to elect three of the five directors in the JV, and Pioneer Idea, has the right to elect the other two directors, with each director having one vote with the exception of certain material corporate actions which will require unanimous approval of the board of the JV.  Crystal Lake is indirectly wholly-owned by Li Ka Shing, and Pioneer Idea is indirectly owned by Solina Chau, and each of Mr. Li and Ms. Chau own through affiliated entities more than 5% of the Company&#8217;s common stock.  The transaction has been approved by the Audit Committee of the Company in accordance with the Company&#8217;s Related Person Transaction Policy and ChromaDex engaged third party advisors to provide certain financial advisory services related to the transaction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to being able to commercialize the Products in the Territory, the JV will have to obtain all applicable regulatory approvals, including &#8220;Blue Hat&#8221; or health food registration with the PRC State Administration for Market Regulation for Products in the name of the Company or its designee (collectively, the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Blue Hat Registration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  If the Blue Hat Registration is not obtained within 24 months of closing (which may be extended by an additional 12 months upon consent of the parties), the JV may repurchase the 11% non-voting interest given to Taikuk for $2. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, at the Closing the Company will enter into a distribution agreement with China National Pharmaceutical Group Co., Ltd. (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sinopharm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) relating to the commercialization of the Products in the Territory on Sinopharm&#8217;s cross-border platform (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cross Border Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and the JV will enter into a distribution agreement with Sinopharm relating to the commercialization of the Products in the Territory (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sinopharm Distribution Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  Upon Blue Hat Registration being obtained, the business of the JV will be to market, sell and distribute the Products in the Territory. Upon completion of the Blue Hat Registration, the parties intend that the Cross Border Agreement will be assigned to the JV.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taikuk would be entitled to certain royalty payments equal to a low single digit percentage based on the Company&#8217;s and the JV&#8217;s net revenue for sales of the Products in the Territory under the Cross-Border Agreement and Sinopharm Distribution Agreement, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the Agreement is qualified in its entirety by reference to the full text of such agreement, a copy of which is attached as Exhibit 10.1 hereto.</span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3c146dd07c40479c9fef3188ecd3193f_86"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 7.01 Regulation FD.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 19, 2022, the Company issued a press release announcing the entry into the Agreement. A copy of that press release is attached as Exhibit 99.1 this Current Report on Form 8-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 7.01 and exhibit 99.1 hereto are being furnished and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exchange Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i3c146dd07c40479c9fef3188ecd3193f_96"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Current Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements with respect to the formation of the JV and the commercialization of the Products in the Territory, the entry into the agreements contemplated by the JV, including the Cross Border Agreement and the Sinopharm Distribution Agreement and, the timing of the Closing. These forward-looking statements are based upon the Company&#8217;s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the satisfaction of customary closing conditions related to the Agreement and obtaining the Blue Hat Registration. Additional risks and uncertainties relating to the Company and its business can be found under the caption &#8220;Risk Factors&#8221; in the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, as filed with the Securities and Exchange Commission and other filings submitted by the Company. Forward-looking statements speak only as of the date of this Current Report, and the Company undertakes no duty or obligation to update any forward-looking statements contained in this Current Report as a result of new information, future events or changes in its expectations after the date of this Current Report.</span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div id="i3c146dd07c40479c9fef3188ecd3193f_74"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-top:0.1pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> Exhibits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:0.1pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.804%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="margin-top:1.05pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="chromadexcdxc-jointventure.htm">J</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="chromadexcdxc-jointventure.htm">oin</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="chromadexcdxc-jointventure.htm">t Vent</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="chromadexcdxc-jointventure.htm">ure </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="chromadexcdxc-jointventure.htm">Agreem</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="chromadexcdxc-jointventure.htm">ent</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> **</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="chromadexcdxc-pressrelease.htm">Press Release </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">**    Certain portions of this exhibit (indicated by asterisks) have been excluded pursuant to Item 601(b)(10) of Regulation S-K because they are both not material and are the type that the Registrant treats as private or confidential.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3c146dd07c40479c9fef3188ecd3193f_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:125.72pt;padding-right:125.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:0.1pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="padding-right:12pt;text-align:justify"><span><br/></span></div><div style="padding-right:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:46.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.734%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CHROMADEX CORPORATION</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: May 19, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;/s/  Kevin  M.  Farr </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name: Kevin M. Farr</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>chromadexcdxc-jointventure.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iaa4dae5ad86f4797bf3ce65e4cbb686b_1"></div><div style="background-color:#ffffff"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY &#91;***&#93;, HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">JOINT VENTURE AGREEMENT</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">THIS JOINT VENTURE AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(this</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) is</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">made as of May 19, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">between Crystal Lake Developments Limited, a company incorporated under the laws of the British Virgin Islands (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Crystal Lake</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), Pioneer Idea Holdings Limited, a company organized under the laws of the British Virgin Islands (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Pioneer Idea</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), Hong Kong Taikuk (China) Group Ltd, a company organized under the laws of Hong Kong (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Taikuk</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), and ChromaDex Corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">CDXC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), a company organized under the laws of Delaware.  Each of Crystal Lake, Pioneer Idea, Taikuk and CDXC are hereinafter referred to as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">RECITALS</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">WHEREAS, CDXC currently holds ChromaDex Asia Limited, a Hong Kong limited company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">ChromaDex Asia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), as a wholly owned subsidiary.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">WHEREAS, the Parties have agreed to establish ChromaDex Asia as a joint venture company (hereinafter referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Joint Venture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), in which CDXC or any of its Affiliates will hold a majority shareholding (initially 71%), Crystal Lake will hold a minority shareholding (initially 10.8%), Pioneer Idea will hold a minority shareholding (initially 7.2%) and Taikuk will hold a minority non-voting shareholding (initially 11%)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">WHEREAS, the Parties intend the Joint Venture to engage in activities to (i) obtain all applicable regulatory approvals required to commercialize the Products in the Territory, including &#8220;Blue Hat&#8221; or health food registration with the PRC State Administration for Market Regulation for Products in the name of CDXC or its designee (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Blue Hat Registration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) in China for all of CDXC&#8217;s current and future proprietary products containing nicotinamide riboside by CDXC, which may include Tru Niagen&#174; in formulations equivalent to a 100mg &#8211; 500mg dosage (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Product(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;)&#59; (ii) enter into a non-exclusive distribution agreement with China National Pharmaceutical Group Co., Ltd. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Sinopharm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) relating to the commercialization of the Products in the Territory  (as defined below) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Sinopharm Distribution Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;)&#59; and (iii) after the Joint Venture has obtained such Blue Hat Registration, to market, sell and distribute the Products in the Territory pursuant to the Sinopharm Distribution Agreement (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">JV Purpose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;)&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">WHEREAS the Parties shall at the Closing make the necessary amendments to and&#47;or restatements of the governing documents of ChromaDex Asia to establish the Joint Venture consistent with the terms of this Agreement, and enter into agreements regarding the shareholders&#8217; rights and obligations, the business scope and governance of the Joint Venture, the marketing, supply and distribution of the Products and other commercial terms (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Operating Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), the terms and conditions to be mutually agreed upon between the Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">WHEREAS, CDXC intends to enter into a distribution agreement with Sinopharm (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Cross Border Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) relating to the commercialization of the Products on Sinopharm&#8217;s cross border platform.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">NOW, THEREFORE, in consideration of the foregoing, the Parties agree as follows&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:54pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ARTICLE I.<br>DEFINITIONS</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">For purposes hereof, the following terms, when used herein with initial capital letters, shall have the respective meanings set forth herein&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, with respect to any person or entity, any other person Controlling, Controlled by or under common Control with such person or entity, including, without limitation, any general partner, managing member, officer, director or trustee of such Person, or any venture capital fund or registered investment company now or hereafter existing that is controlled by one (1) or more general partners, managing members or investment advisers of, or shares the same management company or investment adviser with, such person or entity. For purposes of this Agreement, Crystal Lake, Pioneer Idea and their respective shareholders, beneficial owners and Affiliates shall all be deemed Affiliates of one another. No Party or its Affiliates shall by reason of this Agreement be deemed to be an Affiliate of any other Party or its Affiliates.  The term &#8220;Affiliated&#8221; shall have a corresponding meaning.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Anti-corruption Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means laws, regulations, directives and statutes, in each case, relating to anti-bribery or anticorruption, which apply to the business and dealings of the JV, including laws that prohibit the corrupt payment, offer, promise, or authorization of the payment or transfer of anything of value (including gifts or entertainment), directly or indirectly, to any government official to obtain a business advantage&#59; such as, without limitation, the U.S. Foreign Corrupt Practices Act of 1977, as amended from time to time, the UK Bribery of 2010, as amended and all national and international laws enacted to implement the OECD Convention on Combating Bribery of Foreign Officials in International Business Transactions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">CDXC Net Revenue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the amounts actually received by CDXC from the use, sale, licensing, sublicensing, support, manufacture, supply or other disposition of the Products after deductions as agreed to in the Cross Border Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">CDXC Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means all Inventions and trademarks relating to the Products controlled by CDXC or its Affiliates as of the Closing Date and during the term of this Agreement including all Intellectual Property Rights therein.  The CDXC Technology as of the date of this Agreement shall be as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Annex II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; (and the derivative terms &#8220;Controlling&#8221; and &#8220;Controlled&#8221;) means the direct or indirect ownership of more than 50% of the equity securities or other ownership interests or voting rights of, or the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a person or entity, whether through the ownership of voting securities, by contract or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Intellectual Property Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means all United States and foreign past, present, and future rights of the following types, whether registered and unregistered, which may exist or be created under the laws of any jurisdiction in the world&#58; (a) rights associated with works of authorship, including exclusive exploitation rights, copyrights, applications for copyright registration, design rights, and moral rights, (b) rights in trade secrets, trade dress, color combinations, package or label designs including font type, methods, know how, formulas (including &#8220;one off&#8221; variants), Confidential Information, and know-how (including any techniques, specifications, designs, processes, practical knowledge and skills, or other similar information), (c) patents, patent applications (including reissues, reexaminations, continuations, and continuations-in-part), and any counterparts worldwide claiming priority therefrom, and all rights in and to any of the foregoing, (d) data rights, (e) all other intellectual rights or proprietary rights throughout the world, (f) registered or unregistered trademarks and registered or unregistered service marks , and (g) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2</font></div><div style="text-align:justify"><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:54pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">all past, present and future claims and causes of action arising out of or related to infringement, misappropriation or other violation of any of the foregoing.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Invention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any and all designs, data, information, inventions, improvements, development, know-how, discoveries (whether patentable or not), processes, software, and devices developed by or on behalf of a party.    </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Joint Venture Net Revenue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the amounts actually received by Joint Venture from the use, sale, licensing, sublicensing, support, manufacture, supply or other disposition of the Products after the deductions set forth below&#58; sales returns and allowances actually paid, granted or accrued, quantity and cash discounts for price adjustments, billing errors, rejected goods, damaged or defective goods, recalls, returns, rebates, chargeback rebates, compulsory rebates, reimbursements or similar payments granted or given to wholesalers or other distributors, adjustments arising from consumer discount programs or other similar programs, customs or excise duties, sales tax, consumption tax, value added tax, and other taxes (except income taxes), and charges for packing, freight, shipping and insurance.  Joint Venture Net Revenue will be calculated consistent with its ordinary practice and in accordance with International Financial Reporting Standards.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">OFAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">means the U.S. Treasury Department&#8217;s Office of Foreign Assets Control.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means mainland China and its territories, and, for the avoidance of doubt, does not mean Hong Kong, Macau and Taiwan. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; of an entity means any entity of which common stock or other equity securities having ordinary voting power to elect a majority of the board of directors or other persons performing similar functions are at the time directly or indirectly owned by such entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">U.S. Trade Controls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any laws and regulations administered and maintained by the United States Government and any agency thereof pertaining to economic sanctions and export controls, including, without limitation, the U.S. Department of Commerce&#8217;s Export Administration Regulations and the various economic sanctions programs promulgated by OFAC.</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ARTICLE II.<br>ESTABLISHMENT OF THE JOINT VENTURE</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Formation of the Joint Venture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">As soon as practicable after the execution of this Agreement, each of the Parties shall use commercially reasonable efforts to draft, negotiate and enter into the Operating Agreements on terms consistent with the terms of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">The Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The closing of the establishment and initial financing of the Joint Venture (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) shall take place on July 31, 2022 or on a different date to be mutually agreed upon by the Parties, but in any event no later than September 30, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;). The following events shall be conditions precedent to the Closing&#58;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:29.29pt">The Parties shall have entered into a shareholders agreement reflecting the ownership terms and respective rights, duties and obligations of each shareholder of the Joint Venture consistent with this Agreement and satisfactory to the Parties&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3</font></div><div style="text-align:justify"><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:54pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:26.24pt">The Parties shall have received and be reasonably satisfied with a written analysis of applicable taxes of the Joint Venture prepared by a qualified third party tax advisor&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.19pt">The amendments to and&#47;or restatements of ChromaDex Asia&#8217;s governing documents shall be completed on terms consistent with this Agreement and satisfactory to the Parties and shall have been filed with the appropriate government authorities&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.79pt">CDXC and each of Crystal Lake and Pioneer Idea shall have agreed upon an initial business plan&#59; and </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:26.84pt">CDXC and each of Crystal Lake and Pioneer Idea shall have received and shall be reasonably satisfied with a memorandum from CDXC&#8217;s legal counsel summarizing &#8220;Blue Hat&#8221; product registration process, specifically, applicant entity, process and assignability of the Blue Hat Registration.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Further, as a condition precedent to Closing, CDXC shall request and obtain the necessary approvals from its Board of Directors or appropriate committee, as determined by CDXC in its sole discretion and may also secure a third party independent fairness opinion.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> On the Closing Date&#58; </font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:27.68pt">CDXC or any of its Affiliates (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">CDXC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Designee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:115%;position:relative;top:-3.85pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">shall enter into a license agreement with the Joint Venture reflecting the terms set forth in this Agreement, the key supply terms and other customary terms mutually agreed between CDXC and each of Crystal Lake and Pioneer Idea (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), and shall own an 71% interest in the Joint Venture as consideration&#59; and</font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:28.3pt">Crystal Lake shall subscribe and the Joint Venture shall issue such number of shares representing 10.8% of the enlarged issued share capital of the Joint Venture at an aggregate subscription price of US$1,800,000 payable in cash at the Closing (such consideration, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Crystal Lake JV Funding Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:27.68pt">Pioneer Idea shall subscribe and the Joint Venture shall issue such number of shares representing 7.2% of the enlarged issued share capital of the Joint Venture at an aggregate subscription price of US$1,200,000 payable in cash at the Closing (such consideration, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Pioneer Idea JV Funding Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:28.3pt">In consideration of Taikuk introducing the Parties, arranging the transactions contemplated by this Agreement and for Taikuk&#8217;s other obligations as set forth in this Agreement or any ancillary agreement, (i) Taikuk shall own a 5% non-voting interest in the Joint Venture at the Closing and (ii) CDXC shall make a payment of US$1,000,000 in cash at the Closing to Taikuk&#59; provided, however, that if such Blue Hat Registration is not completed during the Registration Period (as defined below), Taikuk agrees that the Joint Venture shall have the irrevocable, exclusive option to repurchase for cancellation such 5% interest in the Joint Venture held by Taikuk for an aggregate purchase price of US$1.00 in cash to be exercised within sixty (60) days of the end of the Registration Period.</font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:29.52pt">Taikuk shall purchase a 6% non-voting interest in the Joint Venture for consideration of US$1,000,000 in cash at the Closing&#59; provided, however, that if such Blue Hat Registration is not completed during the Registration Period (as defined below), Taikuk agrees that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4</font></div><div style="text-align:justify"><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:54pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">the Joint Venture shall have the irrevocable, exclusive option to repurchase for cancellation such 6% interest in the Joint Venture held by Taikuk for an aggregate purchase price of US$1.00 in cash to be exercised within sixty (60) days of the end of the Registration Period.</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Registration Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. </font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:28.3pt">CDXC shall make a payment of US$1,000,000 in cash to Taikuk upon completion of Blue Hat Registration of the Product in China, allowing the Joint Venture to market, sell and distribute the Product in the Territory&#59; provided, however, that such Blue Hat Registration shall be completed within 24 months following the Closing, which may be extended by 12 months upon the written consent of the Parties (such period, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Registration Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;).  </font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:27.68pt">If (i) Blue Hat Registration is not completed during the Registration Period or (ii) the License Agreement and the supply agreement to be entered into between CDXC and the Joint Venture are terminated, each Party will have the right to cause the Joint Venture to promptly make a pro rata payment of remaining cash on hand in the Joint Venture as follows&#58; (i) to Crystal Lake and Pioneer Idea equally, up to US$1,800,000 in cash to Crystal Lake and up to US$1,200,000 in cash to Pioneer Idea and (ii) the remaining cash on hand to CDXC and the other Parties shall take the necessary action to facilitate such distribution. Following such distributions, the Parties shall use their commercially reasonable efforts to terminate and dissolve the Joint Venture as soon as reasonably practicable.</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Taikuk Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">  </font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:28.3pt">In the event that Joint Venture and Sinopharm enter into the Sinopharm Distribution Agreement relating to the commercialization of the Product in the Territory, Taikuk shall be entitled to receive non-refundable royalties for all sales of the Product from Joint Venture to Sinopharm in the Territory equal to &#91;***&#93; of Joint Venture Net Revenue. Pursuant to the Sinopharm Distribution Agreement, Joint Venture shall pay such royalties accrued on a quarterly basis within sixty (60) days after the end of each Joint Venture fiscal quarter beginning with the quarter in which Joint Ventures realizes Joint Venture Net Revenue from the Sinopharm Distribution Agreement.</font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:27.68pt">In the event that CDXC and Sinopharm enter into the Cross Border Distribution Agreement, CDXC shall pay Taikuk non-refundable royalties for all sales of the Product from CDXC to Sinopharm equal to &#91;***&#93; of CDXC Net Revenue.  Pursuant to the Cross Border Agreement, CDXC shall pay such royalties accrued on a quarterly basis within sixty (60) days after the end of each CDXC fiscal quarter beginning with the quarter in which CDXC realizes CDXC Net Revenue. The Parties agree that upon completion of Blue Hat Registration of the Products in China, CDXC shall assign the Cross Border Agreement and the transactions contemplated thereunder to the Joint Venture without additional consideration.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5</font></div><div style="text-align:justify"><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:54pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:166.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:35.75pt;text-decoration:underline">Preferential Payment to Crystal Lake and Pioneer Idea</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.  In the event of (i) any voluntary or involuntary liquidation, dissolution or winding up of the Joint Venture, (ii) a merger or consolidation in which the Joint Venture or its subsidiary is a constituent party and the Joint Venture issues membership interest pursuant to such merger or consolidation other than a merger or consolidation in which the voting interest or securities of the Joint Venture immediately prior thereto continue to represent at least 50% of the total voting power represented by such voting interest of the Joint Venture or such surviving entity outstanding immediately after such merger or consolidation, or (iii) the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Joint Venture or any subsidiary of the Joint Venture of all or substantially all of the assets of the Joint Venture and its subsidiaries taken as a whole, except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of the Joint Venture (collectively, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Liquidation Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), unless Crystal Lake and Pioneer Idea elect otherwise, before any payment of any amounts in such Liquidation Event is paid to such other members of the Joint Venture, the Parties agree to use any and all rights that such Parties have in the Joint Venture to cause the Joint Venture to pay Crystal Lake and Pioneer Idea out of the assets available for distribution to the Joint Venture&#8217;s members an respective amount equal to the Crystal Lake JV Funding Amount and Pioneer Idea JV Funding Amount (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Liquidation Preference</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;).  The Parties agree that only after the Liquidation Preference is fully paid to Crystal Lake and Pioneer Idea will the Joint Venture&#8217;s other members receive any payment as a result of such Liquidation Event.  Notwithstanding the foregoing, in the event of any Liquidation Event, after the payment of the Liquidation Preference, Crystal Lake and Pioneer Idea shall also be entitled to participate in the distribution of the remaining assets of the Joint Venture available for distribution to the Joint Venture&#8217;s members pro rata in accordance with each member&#8217;s ownership interest.</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ARTICLE III.<br>ACTIVITIES OF THE JOINT VENTURE</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Business of the Joint Venture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Initially, the Joint Venture will be engaged in efforts to obtain Blue Hat Approval and enter into the Sinopharm Distribution Agreement. After the Joint Venture obtains Blue Hat Approval, the business of the Joint Venture is to market, sell and distribute Products in the Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Formation of Joint Venture Subsidiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The Joint Venture may operate the Business directly or through local operating corporations, partnerships, associations, joint ventures or similar entities or arrangements, each serving one or more regions in the Territory, as shall be organized or established by the Joint Venture (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Local Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Business Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The Joint Venture shall operate generally to achieve the goals of the Joint Venture&#8217;s strategic business plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Business Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), which shall initially be the business plan set forth on Annex I to be jointly developed by the Parties and may be reviewed and amended by the Board from time to time. The Business Plan may include such matters as the Board determines, including without limitation, (i) regulatory approval strategy and associated costs, (ii) marketing strategy, (iii) product and technology strategy, (iv) intellectual property strategy, (v) target customers, (vi) capital requirements, (vii) manufacturing facilities and sites, and (viii) detailed budget.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6</font></div><div style="text-align:justify"><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:54pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ARTICLE IV.<br>MANAGEMENT OF THE JOINT VENTURE</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The Joint Venture shall be governed by a Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) consisting of 5 directors.  CDXC shall have the right to elect 3 of the directors (regardless of its ownership interest in the Joint Venture), and Pioneer Idea shall have the right to elect 2 of the directors (regardless of its ownership interest in the Joint Venture).  Upon the mutual written agreement by CDXC and Pioneer Idea, the number of directors on the Board may be increased or decreased and the composition of the Board, including CDXC&#8217;s and Pioneer Idea&#8217;s right to elect directors, may be changed. </font></div><div style="margin-bottom:0.12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:31.25pt;text-decoration:underline">Meetings of the Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The Board shall meet at least once per quarter either in person, virtually or as required by the applicable laws of The Cayman Islands. </font></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Reports to the Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The following transactions shall be reported to the Board, at least on a quarterly basis&#58;</font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:28.3pt">any agreement, arrangement or understanding between the Joint Venture or its Subsidiary and  any Party or any Affiliate of any Party&#59;</font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:27.68pt">any capital expenditure exceeding US$100,000&#59; and</font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:28.3pt">licensing to any third party any Intellectual Property Rights or Trademark Rights of the Joint Venture.</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Matters Requiring Unanimous Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">At meetings of directors, each director has one vote.  In order to protect the financial interest of minority equity holders, the unanimous vote of the Board shall be required to approve the following matters relating to the Joint Venture and its Subsidiaries&#58;</font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:28.3pt">establish, change or modify the JV Purpose or the Business&#59;</font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:27.68pt">adopt, amend or terminate the organizational documents of the Joint Venture or any of its Subsidiaries&#59;</font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:28.3pt">enter into, amend, terminate, or approve any agreement, arrangement, understanding, or transaction between the Joint Venture, its Subsidiary and any Party or its Affiliate and&#47;or any related parties of the Joint Venture and its Subsidiaries including their directors and officers</font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:27.68pt">provide the express prior written consent of the Board required under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 6.2 (Non-Competition)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#59; </font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:28.3pt">acquire or invest in any shares, assets, business or business division or formation of a new subsidiary where the aggregate value of such acquisition or investment is in excess of USD500,000&#59;</font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:29.52pt">enter into, modify or terminate any joint ventures between the Joint Venture or any of its Subsidiaries and the other party&#59;  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;7</font></div><div style="text-align:justify"><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:54pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:27.68pt">sell or divest a business of the Joint Venture or any of its Subsidiaries or merge or consolidate with any other entity where the aggregate value of such is in excess of USD 500,000&#59;</font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:27.68pt">effect a Liquidation Event&#59;</font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:30.13pt">declare or pay any dividend or distributions to the Parties or repurchase any equity of the Parties (except as required by this Agreement)&#59;</font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:30.13pt">admit new members to the Joint Venture&#59;</font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:27.68pt">any transaction or series of transactions with the principal purpose of raising capital, pursuant to which the Joint Venture or any of its Subsidiaries issues and sells interests in the Joint Venture or any of its Subsidiaries&#59;</font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:30.13pt">incur indebtedness or provide guarantees or indemnities to secure the foregoing indebtedness in excess of USD 500,000&#59;</font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:24.63pt">enter into transactions or material expenditures whose aggregate value is in excess of USD 500,000, including, without limitation, contractual arrangements with contract manufacturers and&#47;or service providers for clinical trials and related services&#59;</font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:27.68pt">modify or replace any share option or equity compensation plan, or increase the number of shares available for issuance upon the grant of options, warrants or rights pursuant to such plan&#59; liquidate, dissolve, wind up or file voluntary bankruptcy proceedings with respect to the Joint Venture or any of its Subsidiaries&#59; or</font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:27.68pt">effect public listing of the Joint Venture or its Subsidiaries.</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, the Joint Venture&#8217;s Chief Executive Officer will be authorized to make decisions regarding the day-to-day operations of the Joint Venture without Board approval, including matters customarily considered in the ordinary course of business.  The Board shall appoint the management team of the Joint Venture, including a Chief Executive Officer and a Chief Financial Officer.  The Chief Executive Officer shall also be appointed as the legal representative of the Joint Venture.  The duties of the Chief Executive Officer and the Chief Financial Officer shall be as outlined in the Business Plan.</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Profits</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Cash dividends will be declared by the Board at its discretion, subject to giving priority to reinvestment and dedicated financial reserves, and will be allocated according to ownership percentage subject to any withholding or any other tax under any applicable laws and regulations.  Cash distributions upon termination or liquidation of the Joint Venture will be allocated according to Section 2.5.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:171pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">4.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Anti-Dilution Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.  Notwithstanding anything contrary in this Agreement, in the event of any future issuance of the Joint Venture&#8217;s equity or equity-based securities (other than pre-approved compensatory equity awards), CDXC shall have the option to purchase additional interests in the Joint Venture at the pre-money valuation at the time of the Joint Venture formation to maintain up to 51% ownership&#59; provided, however, that CDXC&#8217;s right to purchase such additional interests shall terminate immediately after the closing of the first equity financing round of the Joint Venture following the date on which Blue Hat Registration is obtained.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;8</font></div><div style="text-align:justify"><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:54pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:166.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:35.75pt;text-decoration:underline">Books and Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.  The Joint Venture shall, and shall require that each Subsidiary shall, make and keep books, records and accounts which, in reasonable detail, accurately and fairly reflect their transactions and dispositions of assets, which comply with applicable laws in relation to such record keeping requirements and devise and maintain a system of internal accounting controls sufficient to provide reasonable assurances that transactions are executed in accordance with management&#8217;s general or specific authorization and are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and practices applicable to the Joint Venture to maintain accountability of such assets.  The Parties agree that (i) management accounts shall be prepared and delivered to the Parties on a monthly basis, (ii) financial statements, including a balance sheet, income statement and cash flow statement, of the Joint Venture and any Joint Venture Subsidiaries shall be prepared within 120 days after the close of each financial year in accordance with agreed accounting principles, and audited by a recognized accounting firm, including to ensure that CDXC can comply with its reporting obligations as a publicly-traded company in the United States of America and (iii) the Joint Venture and any Joint Venture Subsidiaries shall provide timely, accurate and complete responses to requests for any records or information related to the Joint Venture or any Joint Venture Subsidiary.</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ARTICLE V.<br>INTELLECTUAL PROPERTY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:171pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Ownership of CDXC Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The Parties acknowledge and agree that (a) all CDXC Technology shall be solely owned by CDXC, and (b) any Inventions, including the Intellectual Property Rights therein, developed, created, conceived or reduced to practice by the Joint Venture that incorporates, combines, includes, embodies, contains, is based upon, or otherwise relates to CDXC Technology or any other Inventions, and Intellectual Property Rights therein, provided by CDXC to the Joint Venture in connection with this Agreement shall be exclusively owned by CDXC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:171pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">License to Joint Venture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Subject to the terms and conditions of this Agreement and any other existing commitments set forth in Annex III and the Cross Border Agreement, CDXC hereby grants the Joint Venture and its Subsidiaries an exclusive, irrevocable, royalty free, sub-licensable right and license in the Territory under the CDXC Technology to develop, market, sell and distribute the Product solely to the extent necessary for the Joint Venture and its Subsidiaries to perform activities required to accomplish the JV Purpose and Business in accordance with this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:171pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">5.3&#160;&#160;&#160;&#160;CDXC shall grant the Joint Venture a right of first offer to develop, market, sell and distribute CDXC&#8217;s proprietary products containingany ingredients or formulation(s) and any tangible items, which, at any time, incorporate in whole or in part CDXC Technology or any other Intellectual Property Right of CDXC in the Territory, other than nicotinamide riboside or any of its intermediates or coformers, (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">First Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), the terms of the First Right shall be determined and agreed by the parties in the Shareholders Agreement of the Joint Venture&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:171pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">5.4 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">No Implied Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.  Only the licenses granted pursuant to the express terms of this Agreement or any properly adopted ancillary agreement will be of any legal force or effect.  No other license rights will be created by implication, estoppel or otherwise.  Each Party reserves all rights not expressly granted to the other Party under this Agreement.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;9</font></div><div style="text-align:justify"><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:54pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:171pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">5.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">No Contest&#59; Negative Publicity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.  The Joint Venture will not, and will cause the members of the Joint Venture to not, directly or indirectly, contest, challenge or attach CDXC&#8217;s right, title or interest in or to the CDXC Technology or any other Intellectual Property Rights of CDXC.  The Joint Venture agrees that it and any other person acting on its behalf will not, directly or indirectly, engage in any conduct or practice that is disparaging to CDXC, the CDXC Technology or the Intellectual Property Rights of CDXC or otherwise portrays CDXC, the CDXC Technology or the Intellectual Property Rights of CDXC in a negative light.  If the Joint Venture becomes aware that any member of the Joint Venture violates this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, the Joint Venture will exercise all rights that it has to remove such member from the Joint Venture and redeem any interest such member has in the Joint Venture without reimbursement to such member and without recourse.</font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:171pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:31.25pt;text-decoration:underline">Rights to Regulatory Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  CDXC will supply product samples, data and documentation needed by the Joint Venture for application of the Blue Hat Registration.  Notwithstanding anything to the contrary in this Agreement, all regulatory approvals and applications therefor, obtained or completed in connection with the JV Purpose or related to the Product, including any related records (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) shall be owned by CDXC and held in the name of CDXC or its designee.  In the event of termination of this Agreement or the Joint Venture, or any liquidation, dissolution, bankruptcy or similar proceeding or substantial abandonment of discontinuation of the active operations of the Joint Venture, then CDXC shall have the sole and exclusive right to continue maintaining the ownership rights to all such Regulatory Approvals. </font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:189pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:171pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">5.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.  The Parties must keep in confidence and must not disclose to any third party any information whatsoever which is received in connection with the negotiations, the execution or the implementation of the Joint Venture and which is of a technical, financial or business nature and concerns the composition, the manufacture, the application, the distribution or the service of Products, the sources of supply of raw material for products, information on customers or any details of the businesses of the Parties, but does not include information which the Parties hereto have lawfully received from third parties or which is in the public domain (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), except that a Party may make such disclosures as it may in its reasonable discretion determine necessary&#58; </font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:28.3pt">to its professional advisers, auditors, bankers, financial advisers, financiers and Affiliates who need to know such Confidential Information upon those persons undertaking to keep any Confidential Information so disclosed&#59;</font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:27.68pt">to exercise any rights arising out of this Agreement&#59; or</font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:28.3pt">to comply with any applicable law or any requirement of any regulatory body (including any relevant stock exchange)&#59; provided that in the event that any Party reasonably believes that it is required to disclose any Confidential Information, such Party will (i) to the extent permissible, provide the other Party with prompt notice before such disclosure in order that other Party may attempt to obtain a protective order or other assurance that confidential treatment will be accorded to such Confidential Information and (ii) reasonably cooperate with the other Party, at the other Party&#8217;s expense, in attempting to obtain such order or assurance.</font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Upon request of the disclosing party, copies and embodiments of the disclosing party&#8217;s Confidential Information shall be promptly returned to the disclosing party by the receiving party.  Upon expiration or termination of this Agreement for any reason, each party shall promptly return to the other party all Confidential Information of the other party in its possession, including all copies thereof, unless such copies are required to support existing customers under the terms of this Agreement or otherwise required by applicable law or such party&#8217;s documentation retention policies.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;10</font></div><div style="text-align:justify"><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:54pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:171pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">5.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Publicity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.  Before any information is released to the public concerning the Joint Venture, each Party will agree on the content of a joint press release or other forms of publicity.  No Party will issue a press release regarding any matter related to the Joint Venture without the consent of the other Parties, unless otherwise required by applicable laws or regulations.</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ARTICLE VI.<br>COVENANTS</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Restrictions on Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">No Party shall be permitted to transfer, sell, pledge, or otherwise dispose of or give any person, except to its Affiliate(s), any rights in or over its equity interests in the Joint Venture, rights or assets held by the Joint Venture in any way without the express prior written consent of the other Parties.  For the purpose of this Agreement, Crystal Lake, Pioneer Idea, their beneficial owners and their Affiliates shall be deemed as Affiliates to each others.  Any attempt by a Party to transfer, sell, pledge, or otherwise dispose of or give any person any rights in or over its equity interests in the Joint Venture, rights or assets in violation of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> shall be void.  Notwithstanding anything to the contrary contained in this Agreement, no consent shall be required for pledges of assets in connection with disclosed and consensual debt financing transactions of either Party. Standard drag along and tag along rights will be included in the definitive agreement.</font></div><div style="margin-bottom:0.12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Non-Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Each party agrees and acknowledges that so long as this Agreement remains binding on such party, neither CDXC, Crystal Lake, Pioneer Idea, Taikuk or any of their Affiliates shall engage in any transaction in the Territory which is competitive with the Business of the Joint Venture unless otherwise approved by the Board in accordance with Section 4.4(d). For the avoidance of doubt, nothing contained in this Agreement shall limit or prevent CDXC from performing its pre-existing obligations to third-parties, or limit CDXC&#8217;s ability to exercise its rights pursuant to its pre-existing engagements with third parties, in each case, as set forth in Annex III.  For the avoidance of doubt, the restrictions set forth in this section shall not limit or restrict any of Crystal Lake, Pioneer Idea and their Affiliates from acquiring or holding any share capital in a company which engages in businesses which are or may be competitive with the Business of the Joint Venture. Compliance.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The Joint Venture shall maintain and implement policies and procedures reasonably designed to ensure compliance with Anticorruption Laws and U.S. Trade Controls, and shall, and shall procure that each Subsidiary shall, remain in full compliance with (i) all applicable laws and (ii) the CDXC Code of Conduct as in effect from time to time as set forth on CDXC&#8217;s website.</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ARTICLE VII.<br>TERM AND TERMINATION</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">This Joint Venture shall commence on the Closing and shall continue until the 20th anniversary of the Effective Date (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) or until terminated in accordance with the Operating Agreements.</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Each of CDXC, Crystal Lake and Pioneer Idea may terminate this Agreement at its sole discretion by written notice to the other Parties upon the occurrence of any of the following&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;11</font></div><div style="text-align:justify"><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:54pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:28.3pt">any other Party materially breaches this Agreement, and such breach is not remedied within thirty (30) days of the non-breaching Party giving written notice of such breach to the breaching Party&#59; provided, however, that Crystal Lake may not terminate due to a breach by Pioneer Idea, and Pioneer Idea may not terminate due to a breach by Crystal Lake&#59;</font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:27.68pt">any other Party, or any person or entity with Control over any other Party, becomes bankrupt or insolvent, or is the subject of proceedings for liquidation or dissolution only wherein any of which results in an inability of the subject Party to perform the functions of its business in their ordinary course, or ceases to carry on business or becomes unable to pay its debts as and when they become due and payable&#59; provided, however, that, notwithstanding anything to the contrary contained herein, no right of termination shall exist due to the bankruptcy, insolvency, liquidation or dissolution of the investors of CDXC or the members of the CDXC board of directors or their Affiliates&#59; or</font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:28.3pt">any other Party is not in compliance in all material respects with the requirements of all applicable laws&#59; provided, however, that in lieu of terminating this Agreement under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 7.2(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, the complying Parties may elect to terminate such non-complying Party from the Joint Venture and such non-complying Party will forfeit any and all interest such non-complying Party has in the Joint Venture without any additional consideration therefor and without any further action by the Joint Venture. </font></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Termination by Mutual Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">This Agreement may be terminated by the mutual written agreement of the voting Parties.</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Effect of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:28.3pt">Upon termination or expiration of this Agreement for any reason, the Parties agree that, pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, no Party other than CDXC shall have any rights to any Regulatory Approvals.</font></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:27.68pt">Upon termination or expiration of this Agreement for any reason, the Parties agree that the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Article I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Sections 5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">8.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">8.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> shall survive forever, and that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 5.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> (Confidentiality) shall survive for a period of 5 years from the date of termination or expiration of this Agreement.  A termination of this Agreement shall be without prejudice to any rights or obligations that shall have accrued or become due before the termination of this Agreement.</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ARTICLE VIII.<br>MISCELLANEOUS</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">This Agreement together with any documents referred to herein or executed contemporaneously in connection with this Agreement constitutes the entire agreement between the Parties with respect to the subject matter of this Agreement and supersedes, cancels and replaces any other prior written or verbal understandings, agreements, representations and correspondence between the Parties.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;12</font></div><div style="text-align:justify"><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:54pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">All notices, demands and other communications to be given or delivered under or by reason of the provisions of this Agreement shall be made in writing or electronically and shall be deemed to have been given (i) on the date of actual delivery, when personally delivered or transmitted by facsimile, or in the case of an internationally recognized courier service, (ii) on the 7th business day from the date of posting in the case of pre-paid first class post, special delivery or registered post, or (iii) on the date of receipt by email transmission.  </font></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Amendment and Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Except as otherwise expressly provided in this Agreement, any provision of this Agreement or the annexes, schedules or exhibits may be amended or waived only in a writing signed by all of the Parties.  No waiver of any provision hereunder or any breach or default thereof shall extend to or affect in any way any other provision or prior or subsequent breach or default.</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">No Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, no Party may assign or transfer, or grant any security interest over, any of its rights and&#47;or obligations under this Agreement without the prior written consent of the other Parties. Notwithstanding the above, (i) nothing contained in this Agreement shall limit or prevent any Party&#8217;s ability to assign, sell, or delegate to its Affilite its rights and obligations in any matter whatsoever, including this Agreement and CDXC&#8217;s interest in the Joint Venture, which it may determine in its sole discretion, and (ii) none of the following shall be considered an assignment of this Agreement or any Party&#8217;s interest in the Joint Venture&#58; a change  of control of such Party, a sale of or  take private transaction of such Party, or the sale of all or substantially all of the assets of such Party.  </font></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">8.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">This Agreement shall be construed, interpreted and governed by the laws of Hong Kong.</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">8.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Any dispute, controversy or claim arising out of or relating to this contract, or the breach, termination or invalidity thereof, shall be settled by arbitration in Hong Kong and by the rules of arbitration governed by the Hong Kong International Arbitration Centre (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">HKIAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;).  The arbitration panel shall consist of three arbitrators with Crystal Lake, Pioneer Idea and CDXC each having the right to appoint one arbitrator who shall then jointly appoint the third arbitrator, failing which the third arbitrator shall be appointed by the HKIAC.  The arbitration proceedings shall be conducted in English.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;13</font></div><div style="text-align:justify"><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:54pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">8.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:31.25pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Except as otherwise provided herein, this Agreement is binding upon, and inures to the benefit of, the Parties and their respective permitted successors and assigns.</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">*  *  *  *</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;14</font></div><div style="text-align:justify"><font><br></font></div></div></div></div><div id="iaa4dae5ad86f4797bf3ce65e4cbb686b_4"></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Parties have executed this Joint Venture Agreement on the day and year first above written.</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Crystal Lake Developments Limited</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Neil McGee&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> Neil McGee&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Its&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> Director &#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Pioneer Idea Holdings Limited</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; .</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Raymond Ng&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> Raymond Ng&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Its&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> Authorized Signatory&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">ChromaDex Corporation</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> &#47;s&#47; Robert Fried&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> Robert Fried&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Its&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> Chief Executive Officer &#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Hong Kong Taikuk (China) Group Ltd.</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> &#47;s&#47; Zheng Tian Yi&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> Zheng Tian Yi&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Its&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">  Director &#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>chromadexcdxc-pressrelease.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i91573d58c0c04d249badb7bc340f79bc_1"></div><div style="min-height:46.8pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 99.1</font></div></div><div style="text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:50px;margin-bottom:5pt;vertical-align:text-bottom;width:221px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ChromaDex Announces Agreement to Launch Commercial Joint Venture in Mainland China</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The signed agreement establishes beachhead to broadly market and distribute Tru Niagen&#174; to Mainland China&#8217;s aging population</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LOS ANGELES, CA - May&#160;19, 2022 - </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ChromaDex Corp. (NASDAQ&#58;CDXC) (&#8220;the Company&#8221;) a global bioscience company dedicated to healthy aging, today announced it has entered into an agreement (the &#8220;JV Agreement&#8221;) to establish a joint venture through its wholly owned subsidiary ChromaDex Asia Limited (the &#8220;JV&#8221; or &#8220;ChromaDex Asia&#8221;). Upon establishment of the JV, membership of ChromaDex Asia will collectively consist of the Company&#59; Crystal Lake Developments Limited&#59; Pioneer Idea Holdings Limited&#59; and Hong Kong Taikuk (China) Group Limited. ChromaDex Asia is expected to assume the distribution agreement noted in a previous announced press release with Sinopharm Xingsha (&#8220;Sinopharm&#8221;) as it relates to the commercialization of Tru Niagen&#174; in mainland China and its territories, excluding Hong Kong, Macau and Taiwan (the &#8220;Territory&#8221;).  The JV&#8217;s entry into a distribution agreement will be contingent upon Sinopharm successfully attaining health food product registration for Tru Niagen&#174; with the People&#8217;s Republic of China&#8217;s State Administration for Market Regulation (&#8220;SAMR&#8221;). SAMR is the regulatory body responsible for health food registration. Health food registration is a key regulatory step required to be able to broadly market and distribute Tru Niagen&#174; products in China.  Formation of the joint venture is subject to customary closing conditions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;The establishment of this joint venture marks an expansion milestone in ChromaDex&#8217;s China strategy and sets the necessary foundation to advance sales of Tru Niagen&#174; in this key market,&#8221; said Rob Fried, CEO of ChromaDex. &#8220;We are honored to extend our professional relationship with existing strategic partners, as well as our new partner in this venture, Taikuk.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For detailed transaction terms, see 8-K (filed on May 19, 2022).</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Important Note on Forward Looking Statements&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements with respect to the formation of the JV and the commercialization of the Products in the Territory, the entry into the agreements contemplated by the JV, including the distribution agreements and, the timing of the closing of the JV Agreement. These forward-looking statements are based upon the Company&#8217;s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the satisfaction of customary closing conditions related to the Agreement and obtaining the health food registration. Additional risks and uncertainties relating to the Company and its business can be found under the caption &#8220;Risk Factors&#8221; in the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, as filed with the Securities and Exchange Commission and other filings submitted by the Company. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in its expectations after the date of this press release.</font></div><div><font><br></font></div><div style="height:115.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><img alt="image_1.jpg" src="image_1.jpg" style="height:40px;margin-bottom:5pt;vertical-align:text-bottom;width:39px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">About ChromaDex&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ChromaDex Corporation is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. NAD+ levels in humans have been shown to decline with age, among other factors, and may be increased through supplementation with NAD+ precursors. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen&#174;. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex&#8217;s patent portfolio. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company delivers Niagen&#174; as the sole active ingredient in its consumer product Tru Niagen&#174; available at </font><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">www.truniagen.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and through partnerships with global retailers and distributors. The Company also develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Company further offers natural product fine chemicals, known as phytochemicals, and related research and development services. Follow us on Twitter &#64;ChromaDex and Instagram &#64;TruNiagen and subscribe to our latest news via</font><font style="color:#ff0090;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our website accessible at&#160;</font><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">www.chromadex.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;to which ChromaDex regularly posts copies of its press releases as well as additional updates and financial information about the Company.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Contacts&#58; </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investor Relations</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Media Relations</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brianna Gerber</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kendall Knysch</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President of Finance and Investor Relations</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director of Media Relations</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949-419-0288 ext. 127</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310-388-6706 ext. 689</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">briannag&#64;chromadex.com</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">kendall.knysch&#64;chromadex.com</font></td></tr></table></div><div style="height:115.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><img alt="image_1.jpg" src="image_1.jpg" style="height:40px;margin-bottom:5pt;vertical-align:text-bottom;width:39px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>cdxc-20220519.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:f0c1e2ed-9b8f-4ae5-8f58-6ccc4c4ae049,g:80676cc1-0433-417f-a180-197fa0d0234f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cdxc="http://chromadex.com/20220519" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://chromadex.com/20220519">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdxc-20220519_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdxc-20220519_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://chromadex.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>cdxc-20220519_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:f0c1e2ed-9b8f-4ae5-8f58-6ccc4c4ae049,g:80676cc1-0433-417f-a180-197fa0d0234f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementTenderOffer_96f42a83-e0b9-4cf2-b564-b1eec4fff3cf_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e6f049d9-7ce1-4e24-902d-c4f7c6263060_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5d94223b-9f4a-4792-beac-4dcd234d4bbb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_96cb94e3-b8f5-4fdd-938e-7d6328c80bde_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_9e86efcd-ca58-40e3-9c37-596ba12661c4_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_79dfd83f-e4be-48d3-a232-dcc952996f1e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_ff9e3cca-fc8e-4a60-9aba-5bc23aa6e968_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_646f5ac8-437a-4501-b8f5-6878e962cdde_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b5c874b3-822b-4cf3-956e-adb6f12335ee_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_bb4fd42c-3faa-49eb-bbfd-272f50f4f2a6_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_02d7423f-e379-4a17-b565-4de58d76edb0_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_ec31aad5-88fb-4c9d-9534-13c9a8678e1a_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_382af457-7006-4f71-8b09-7a6812ce5461_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a7249f6e-04d2-400e-88e5-6109006b398b_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7817b148-d097-4c60-8f50-ccc0fe5ac2df_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e1a1d39d-d53c-4410-b052-73383b9fa55c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4e2f133d-d915-4bc6-b180-3ad2c6ce32f7_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_51964960-bd9f-4dd5-af70-b66848af8cb7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c94412be-a1e4-40ac-873b-91611b9876f9_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_4e46fad3-4292-41b3-b5fd-12085f7c148a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_948908b4-aa2f-441d-afef-be4c502af664_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_bacecffd-9c29-4626-a62b-4db8385689b8_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>cdxc-20220519_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:f0c1e2ed-9b8f-4ae5-8f58-6ccc4c4ae049,g:80676cc1-0433-417f-a180-197fa0d0234f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://chromadex.com/role/Cover" xlink:type="simple" xlink:href="cdxc-20220519.xsd#Cover"/>
  <link:presentationLink xlink:role="http://chromadex.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_245f8942-4a16-4ba4-b465-d66cd1cbeff0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f0500898-7dc8-4bd6-97f6-329c08279a0d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_245f8942-4a16-4ba4-b465-d66cd1cbeff0" xlink:to="loc_dei_DocumentType_f0500898-7dc8-4bd6-97f6-329c08279a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b1752263-2d48-4cad-a24f-b6c2c405fc2e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_245f8942-4a16-4ba4-b465-d66cd1cbeff0" xlink:to="loc_dei_DocumentPeriodEndDate_b1752263-2d48-4cad-a24f-b6c2c405fc2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_fc847993-072c-4ac7-b3bb-f3a90ddc2aff" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_245f8942-4a16-4ba4-b465-d66cd1cbeff0" xlink:to="loc_dei_EntityRegistrantName_fc847993-072c-4ac7-b3bb-f3a90ddc2aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_6e130dd3-096b-4f2f-ae98-421e303f761b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_245f8942-4a16-4ba4-b465-d66cd1cbeff0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_6e130dd3-096b-4f2f-ae98-421e303f761b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c8f6cd16-6684-43a8-b542-165a7a652eb9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_245f8942-4a16-4ba4-b465-d66cd1cbeff0" xlink:to="loc_dei_EntityFileNumber_c8f6cd16-6684-43a8-b542-165a7a652eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_99d781cd-2159-47ed-ade3-02209485217f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_245f8942-4a16-4ba4-b465-d66cd1cbeff0" xlink:to="loc_dei_EntityTaxIdentificationNumber_99d781cd-2159-47ed-ade3-02209485217f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d8e30e68-b2cd-4be5-89ba-60c938da8440" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_245f8942-4a16-4ba4-b465-d66cd1cbeff0" xlink:to="loc_dei_EntityAddressAddressLine1_d8e30e68-b2cd-4be5-89ba-60c938da8440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_8f1a3087-2285-4a36-b806-cab168dd5959" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_245f8942-4a16-4ba4-b465-d66cd1cbeff0" xlink:to="loc_dei_EntityAddressAddressLine2_8f1a3087-2285-4a36-b806-cab168dd5959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_bf968505-6bf8-4d3e-8909-3cc39584cbdf" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_245f8942-4a16-4ba4-b465-d66cd1cbeff0" xlink:to="loc_dei_EntityAddressCityOrTown_bf968505-6bf8-4d3e-8909-3cc39584cbdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5f67cfea-2a8d-414a-b8d8-ea18b79ba467" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_245f8942-4a16-4ba4-b465-d66cd1cbeff0" xlink:to="loc_dei_EntityAddressStateOrProvince_5f67cfea-2a8d-414a-b8d8-ea18b79ba467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b33c0f8b-fd8d-40f9-b65d-caa5c0696c87" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_245f8942-4a16-4ba4-b465-d66cd1cbeff0" xlink:to="loc_dei_EntityAddressPostalZipCode_b33c0f8b-fd8d-40f9-b65d-caa5c0696c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_7f0a0709-982c-42ac-87b6-732ebe2fe498" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_245f8942-4a16-4ba4-b465-d66cd1cbeff0" xlink:to="loc_dei_CityAreaCode_7f0a0709-982c-42ac-87b6-732ebe2fe498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_2e83f2d9-7f70-4887-82e9-ab99d386627d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_245f8942-4a16-4ba4-b465-d66cd1cbeff0" xlink:to="loc_dei_LocalPhoneNumber_2e83f2d9-7f70-4887-82e9-ab99d386627d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_ae29a808-140e-4da8-9a9d-bc9ed676e889" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_245f8942-4a16-4ba4-b465-d66cd1cbeff0" xlink:to="loc_dei_WrittenCommunications_ae29a808-140e-4da8-9a9d-bc9ed676e889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_7874b54b-4189-442e-864e-9217407ad09a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_245f8942-4a16-4ba4-b465-d66cd1cbeff0" xlink:to="loc_dei_SolicitingMaterial_7874b54b-4189-442e-864e-9217407ad09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_b8f62d44-4cef-42a2-8721-4c418a70521b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_245f8942-4a16-4ba4-b465-d66cd1cbeff0" xlink:to="loc_dei_PreCommencementTenderOffer_b8f62d44-4cef-42a2-8721-4c418a70521b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_4d2cae0c-3804-4652-8b36-11ace9165ec9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_245f8942-4a16-4ba4-b465-d66cd1cbeff0" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_4d2cae0c-3804-4652-8b36-11ace9165ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_46201051-062e-43db-9499-92e5b32d3260" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_245f8942-4a16-4ba4-b465-d66cd1cbeff0" xlink:to="loc_dei_Security12bTitle_46201051-062e-43db-9499-92e5b32d3260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a8621c00-fa53-4240-80f0-79674ec6a626" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_245f8942-4a16-4ba4-b465-d66cd1cbeff0" xlink:to="loc_dei_TradingSymbol_a8621c00-fa53-4240-80f0-79674ec6a626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_5e50757d-679d-4118-b376-e5bdc91ae96b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_245f8942-4a16-4ba4-b465-d66cd1cbeff0" xlink:to="loc_dei_EntityEmergingGrowthCompany_5e50757d-679d-4118-b376-e5bdc91ae96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a6096a81-7921-443a-b147-5678f225244f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_245f8942-4a16-4ba4-b465-d66cd1cbeff0" xlink:to="loc_dei_EntityCentralIndexKey_a6096a81-7921-443a-b147-5678f225244f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3f1a14b2-ad5c-4555-bba5-db98e8565956" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_245f8942-4a16-4ba4-b465-d66cd1cbeff0" xlink:to="loc_dei_AmendmentFlag_3f1a14b2-ad5c-4555-bba5-db98e8565956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" !R ?L# 2(  A$! Q$!_\0
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MJV4X23I/:K5?LXM=XIIS:ML^5)]SQ<QSW+<M;A4E>:^S'6WJ]E]Y_3+XS_:
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M **** "BBB@ HHHH **** "BBB@ HHHS0 449'K1D>M !1110 4444 %%%%
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MOQ*Z1I_N@J<#\:^D?V#_ -A3X4?\$^OA!??!#X,ZMJ]UH=WX@FU:)=8N1+)
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M8?Q->Z/)>S7@#,"R6Z\1QGY-K,0<@\8(KX,_X+A_LW_#_P#95_X*3>/?AO\
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MM[JSNH6BN+6YA$D<J$8*LI!!!]#P0:_F+_X*S_";1?\ @G]_P5F\0GX'6O\
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M?YGQV(PM7"\.P<U9RFI6]=$?TL1#$:X'\-.IL?\ JU_W:=7P9^C1^%'\U/\
MP<M$_P##UKQ2/^I:T7_TE2OZ4;?'EKQ7\UW_  <L<_\ !5OQ21_T+.B_^DJU
M_2C;?ZM17T.<?\B_"?X7^43YG(_^1IC/\2_.0_MC_9K^;'_@Y@_Y2H^(L?\
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M=BX]*7YL=:_/=?\ @YB_X)B*H7_A*/%W_A-__;:&_P"#F/\ X)BXX\4>+_\
MPF__ +;7RW]EYA_SZE]Q]E'.LKLOWT?O/T%9@%WL.@K\._\ @[)_:.\/Z_\
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M:E&U]WNSP<=FF-S&5Z\KVZ;)?("<G)H.2V5HR#QGK7UW_P $DO\ @E#\3_\
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MR?*]UT,IX/"U:RJS@N9;/J5X=.MHG:?[.JRMCS&"\G'3)[^E6Z**P.D****
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M6KW;W?\ P!W7FB@?2BO//4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH /?%%%% !2/]VBB@"+ W
M=.U.P-G3O110 Y.M.HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
D* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_1.jpg
<TEXT>
begin 644 image_1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X2E*17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(Q.C V.C(S(#$S.C,R.C U   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,U,0  DI(  @    ,U,0  H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,3HP-CHR,R Q,3HP,SHR.0 R,#(Q.C V.C(S(#$Q.C S.C(Y      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  %YT         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ T@#. P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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M]/7V]_CY^O_:  P# 0 "$0,1 #\ ]_HH ** "B@ HH ** "B@ HH ** "B@
MHH ** "B@ HH ** "B@ HH ** "B@"I+J-G#Q)=1@CL&R:RK_P 9Z#IJYN]0
MCB'^T=I/YUQ2Q]!3]G%\TNRNW^ /179SES\9O"5N^U9;R?'4Q0<?J14:?&OP
MFQP1J">[0#^C&O2A1J2C=JQS/%4T:EI\5/!EV0JZRD3'M-"Z?J1C]:Z6PU?3
M=43=I^H6MTN.3!,KX_*IE3E'=&L*L)[,O45!H%% !10 44 %% !10 44 %%
M!5.[U*ULA^^E ;LHY)K&O7IT(.I4=D-*YSNH^+A;P/*/*MH5'S2S,./Z?SKS
M;7OBM#N:.S,U\XXWNVR,?0=_R'UKPZ*Q><5'&'N4EOY^7F_+8BM5C16NK.$U
M'QKKNHLP:\:",_\ +.W^0#\>OZUS[,SL6=BS'DDG)-?6X+ 4,'#DHJWGU9Y5
M2K*H[R$HKL,@IR2/$ZR1NR.IRK*<$4#.MT7XF^*]$*K'J3W4*_\ +*\_>@_B
M?F'X$5Z?X=^-ND7Y6'6K9]/F/'FIF2(_U7\B/>N6KAT]8'71Q+6DSTVTO+:^
MMDN;2>*>!QE)(G#*WT(JQ7%ZGH+R"B@ HH ** "B@ HH *AGN(K6(RS.%0=S
M45)QIQ<Y;(#F;_Q%-,62T!BCZ;S]X_X5POB?Q9;:!%A_W][("4AW<_5CZ?J?
MU'R+G5S;%QI1=H_DNK]?^&*G-4H.3/(]6US4-;N#->SE\'*QCA$^@K.K]"P]
M"GAZ:I4U9(\2<W-\SW"BMB HH ** "B@#:\/>*]9\+W0GTJ\>($@R0GYHY/]
MY>GX]1V(KWGP5\4M+\4;+.["V&J' $3-\DI_V&]?8\_6N7$4;KG6YV8:MROD
MEL>@45Q'H!10 44 %% !10!0U'4X=.BR_P TA^Z@/)KCKN]GO93),V?[JCH/
MI7RV>8UM_5H/;?\ R-(KJ9&MZI'HVCW%\X!\M?D4_P 3'@#\_P!*\*O+N>_N
MY;JYD,DTK%G8UZ7"F'2A.N]WI^K_ $.#'SU4$045]<><%% !10 44 %% !0"
M58$$@@Y&.U 'LGP\^+31-%I'B6?,9PL-\YY7T$GM_M=N_'(]N!#*"""#T([U
MYU:GR2\CU</4YXZ[H6BL3<** "B@ K.U34TTZ'/#2M]Q?ZGVKFQ>(6'HRJ/H
M-*[.,FFDN)6EE8LY/)IE?GTYRG)RENS8XKXFLZ^'+<+]PW2AC_P%J\HK]"X;
MM]07JSQ\;?VH45[YR!10 44 %% !10 44 %>O?"KXCM9RP^'=:G)M7(2TN'/
M^J/9&/\ =]/3ITZ95H<\#?#SY)ZGNM%>:>J%% !10!6O+N.RMFFD/ Z#U/I7
M#75S)=W#32MEF/3L!7R^?XC6-!/S?Z&D%U(J*^;+,?Q/I)UKP_=6B#,Q >+_
M 'AR/SZ?C7AC*R,592&!P01@BONN%:RE0G2>Z=_O7^:/+Q\;34NXE%?4G %.
M1'D<(B,['HH&2:!F@GA[6Y%#)H^H,IZ$6SD']*CN-&U2T4O<Z;>0J!DM) RC
M]14J<>Y7)+L4:*H@** "B@ HH ^A/A+XZ.O:?_8NHRYU&T3,;L>9XQW_ -X=
M_P #ZUZ?7F58\LVCUZ,^:"845F:A10!Q6M:A]MN]J']S$<+COZFLVOS[&U_;
MXB=3HW^'0V2L@HKD&%>=^.O"#R/+K&G1[B<M<PJ.2?[X_K^?K7LY'C%A<8G+
MX9:/Y[/[SGQ5/GIONCS>NH\+> M=\6N&LK<1V@.&NYOEC'T[L?I^.*_2)S4%
M=GCP@YNR/8] ^#/AS2U634?,U2X Y,IV1@^R#^I-=Y9:98:9'Y=A96]JG]V&
M)4'Z5YU2K*;UV/4IT8TUH7**S-3%U7PGH&MJW]HZ1:3L>LACVO\ ]]#!'YUY
MGXD^!L3*\_AV\*/U^RW1RI_W7ZC\<_45M2KN+L]CGJX>,]5HSR#5M'U#0KY[
M+4[22VN$Y*N.#[@]"/<9JC7H)IJZ/-DFG9A13)"B@"[I&J76B:M:ZE9OLN+>
M0.I['U!]B,@^QKZRT#6;?Q#H=IJEJ?W5Q&&VYY4]&4^X((KCQ4=I'=@Y;Q-2
MBN0[@K*UV]^R:>54XDE^5?ZUR8ZK[+#SGY#6K.-HK\^-@HH ** ,&#P)X<G\
M1QZA?12"WZR6R?ZMFSU/?'J!_CGUZV2WCM8TM5C2!5PBQ@!0/;'%?<Y7F3Q=
M%0F_>C^/F<RHQIMM=2>BO3*"B@ HH QO$/AK2_%&G-9:G;"1.=D@X>,^JGL?
M\\U\W>-? ^H>#=0"3?O[*4G[/<J,!O9O1O\ (KJPU2SY6<>*I77.CEJ*[3SP
MHH *]@^!WB5H;ZY\.7#?NYP;BVR>CC[R_B.?^ GUK*O&\&;X>7+41[G17FGJ
MA7%Z]=?:=3=0<I%\@^O?]:\3/JG+AE'NRX;F917QQH%% !10 5;L=2N;!\PO
ME2<LAZ&MJ%>="HJD-T#29TUCKEK>81SY4I_A8\'Z&M:ON\%BZ>*I\\/FNQBT
MT%%=8@HH *S-<T2Q\0Z1/INH1>9!*,?[2'LR^A'K33:=T*235F?*_B?P[=^%
M]>N-+N^6C.8Y .)$/W6'U_0Y':L>O5C)25T>-*+BV@HIDA6AH>J2Z)KEEJ<.
M3);3+( .,@'D?B,C\:35U8J+L[GU[;7$5W:Q7$+!HI4$B,.ZD9!J:O)/:1#<
M2B"WDE/1%+?E7GS,79F)R222?6OE^(9^]3AZO\C2 45\V6%% !10 44 %7[/
M6+RSP%??&.-CY.*Z<-BJF&J>TI_\.)I,W[3Q#:3X67,#G^]]W\ZUD=74,C!E
M/0@\&OM<%CJ>+A>.CZHR::'T5W""B@#S;XQ>%UUCPP=5A3-WIH,A('WHC]\?
MA][\#ZU\ZUWX:5X6['FXJ-JE^X45T'*%% 'TY\*=4.J?#W3][;I+7=;/STVG
MY?\ QTK7;UY=16FSV*3O!&5X@E,>DR '!<JH_.N-KXO/I7Q*79+\V=,-@HKQ
M"@HH ** "B@ HH *FM[NXM3F"9T]0#P?PK2G5G2DIP=F@>IL6WB>9,"XA5Q_
M>3@_Y_*M:WUVPGP/.\ICVD&/UZ5]3@<[A4]S$:/OT_X'Y&;@S01U=0R,&![@
MYI]>\FFKH@0@,I! (/4'O6'?>#O#6I9-WH=@['JXA56_[Z&#51DXO0F48R7O
M'-7OP9\(77^I@N[//_/"X)_]#W5SMY\!+9N;+7IH_:>W#Y_$$?RK>.)DMSFE
MA(/X3"NO@7XAB)-MJ&G3J.FYG1C_ ..D?K6+<?"+QG!G;IB3 =XKF/\ J0:W
MCB8/?0PEA:BVU/3_ (0:+K>@:?JEAJ]C+:J9DFBWD$,2N&Q@G^ZM>F5R56G-
MM';134$F8/BAL64*^LF?R!_QKEJ^&SM_[6_1'5#8**\@H** "B@ HH ** "B
M@ HH ?'-+"<Q2.A_V6P:T(=?U"' ,HD [2+_ )-=F&Q]?#?PY:=N@G%,OQ>*
M3P)K8'U*-_0U>C\1V#_>:2/_ 'DS_+-?08?/J4M*RY7]Z_S(<&6X]2LION74
M1/H6P?UJTK!ERI!'J#7LT<12K*].29-F.HK<044 <_XI_P"/:#_?/\JYBOB<
MZ_WR7R_(UCL%%>24%% !10 44 %% !10 44 %% !10  %C@ DGH!S5J&ROB<
MPV\X]PI K:C1JU'^Z3;\@=NII0V6O#&UYE'^U*#_ %J_%;Z\/OW<&/1AD_RK
MZ'"X?-8_:LO-W_S(;B7HTU(?ZR>W/TB)_K5M-^W#LK-ZJN!_6O=HQKK^+)/T
M5OU_0AF+XG7-A$_]V7^8-<K7R6=JV+?HC2&P45Y!044 %% !10 44 %% !10
M!:ATR]N,&.WD(/0D;1^M:4/AFY;F::.,>V6(KU<+E&(KZR]U>?\ D2Y)%^+P
MS:KS+)+(?0':*NQZ/81?=M4)_P!KYOYU]#A\FPU+XES/S_R(<FRY'''&,(BH
M/0#%/KU(Q459$A15 %% &9KL7FZ1-CJF&'X'_P#77%U\AG\;8B+[K]6:0V"B
MO"+"B@ HH ** "B@ J]:Z1>W6"D)13_$_P HKHPV&JXF?)25V)M(V;;PQ"F&
MN)6<_P!U/E%:T%A:VH_<P(A_O8Y_/K7UV"RJCAES2]Z7?_(S<FRU17K$D-Q/
M#:V\EQ<2)%#$I=Y'. JCDDGTKC;[XM>#K+(74FN7'\-O"S?J0!^M7"G*>R,Y
MU8P^(YJ^^/.F1Y%AHMW/CH9Y%B!_+=7.WGQVUV4D6>FV$"G_ )Z;Y"/U _2N
MF.%_F9RRQ?\ *C!NOBSXSN<XU58%/\,,$8_4@G]:QKCQKXHN<^;X@U$@]0MR
MR@_@#6T:,(]#GE7J2ZGL'P1-[=:/JNHWES/<&6X2)6FD+GY%SW_WQ_D5ZM7#
M6MSNQZ-"_LU<CFB6:&2-ONNI4_C7GTB-%*T;##*Q4CZ5\IQ##6G/U7Y'3 ;1
M7S1844 %% !10  %B  23P .2:V++P]<SX><^2GH1\Q_"N[ X&IBY\L=NK$V
MD=!::39V>"D09Q_&_)J_7VV&PU/#PY*:LC)ML**Z!!10!Y1\:?%:V&CIX?MG
M'VF] >?!Y2('_P!F(Q] ?6O Z]##QM#U/+Q4KU/0**W.<** /J/X9:6=)^'^
MEQLN))XS<O\ \#.X?IBNPKRIN\FSV::M!(*X_P 0VOD:AYH&$F&[\>_^?>O$
MSVGSX7F[-?Y&L-S(HKXPU"B@ HH *TM/T6XO<2-^ZA/\9')'L/ZUU8/"3Q55
M4X_-]D)M)'46>FVUBF(H_FQ@N>2:NU]WAZ$*%-4X+1&3=PHK<044 %8'BSQ1
M9>$M$DU&\.6^[#"#S*^.%']3VIQ3DTD3.2C%MGRSK&K7>N:M<ZG?2;[BX?<Q
M'0#L![ 8 JC7JI)*R/'DVW=A13)"M;PQHS^(?$MAI: XN)@'(ZA!RQ_!0:4G
M9-E15Y)'UTB+%&L<:A44851V I]>2>T%9VKV7VZP=5&9$^9/KZ5S8NE[:A.G
MW0UN<317YX;!10 4R21(HVDD=415)9B< "FDV[(#D;?XH:79^)(TDLFN-,4[
M7F!^;/\ >5>X'/7D_AS[5I>JV.LV$=[IUU%<6S_=>,Y&?3V/M7W^!RUX*@K_
M !/?_+Y''"NJDFB]178:A10 44 <MXN\=:3X0M";J037C#]U:1L-[>Y_NCW/
MX9KYO\3^*-2\5ZJU]J,N<<11+PD2^BC^O4UV8:FU[[.'%5?L(Q:*ZSA"B@ K
MVSX'^&"D5SXDN$QO!M[7([?QM^>!^!K'$2M!G1AHWJ(]GHKSCU HH Y#7].^
MS7/VF-?W4AR0.S?_ %ZQZ^!S&A['$SATW^\VB[H**X1A7E/CGQ6VHW+Z79.1
M9Q-B5@?]:P_H/UZ^E>_P[A%7Q?/+:&OSZ?Y_(Y<74Y:=ENSB:U=#\1ZMX;N_
MM.E7DENQ^^HY23_>4\&OT.45)69Y$9.+NCUO0?CK;2JL6O:<\3]#/:?,I^JG
MD?F:[[3_ !]X4U- ;?7;(9Z+-)Y3?D^#7!4H2CJM4>C2Q,9;Z,W$U"SD3<EW
M;LI[K("*AN=9TNS4M<ZE9PJ!DF2=5'ZFL>5LZ')+<YG5/BKX1TM6']I"[D'_
M "SM%,F?^!<+^M>:>)/C7JVHJUOHENNG0GCSF(>4_3LOZ_6NBEAVW>1R5L2D
MK0/,)[B:ZG>>XE>6:0EGDD8LS'W)J.NY:' [L**!!10!K>&]!NO$VO6NEV@P
M\S?.^,B-!]YC]!^9X[U]8:9IUMI&F6VGVB;+>WC$:+["N/%2U43OPD='(NT5
MR':%% $-Q!'<P-#*N488(KB+^RDL+DQ/R.J-ZBOG,_PUXQKKIH_T+@^A5HKY
M8T,#QEJCZ3X:N)HFVS2XAC/<%L_TS7B5?>\+4E'"RJ=9/\CRL=*\T@HKZ8X0
MHH ** "B@ HH ** "G(C2.L<:EV8@*H&230,^E/ACX('A/1OM%X@_M6[4&8]
M3$O:,?S/J?H*[VO+J2YI-GKTH<D$@HJ#0** "J=_8Q7]L8I!@]58#E36->C&
MM3=.6S!'&7EG-8SF*9<'J".AJO7Y]6I2I3=.6Z-UKJ<7\3(G?P[!(N2L=RI8
M#H,JPS_GUKR>OO\ AJ2> 7JSQ\;_ !0HKWSD"B@ HH ** "B@ HH !R<"O=O
MA9\-FTWR]?UN#%X0&M+9Q_J1_?8?WO0=OKTPKSY8>IT8:'-/7H>NT5YYZ@44
M %% !10!5O+.&^@,4RY'4$=1]*Y#4=*GT]\L-\)/$@'\Z^<SS!.4?K$-UOZ=
M_D7%]#&U+3X=5TV>RG'[N9-N>I4]C^!Q7A>JZ7=:-J$MG=IM=#\K=G'8CV-=
M'"N*5YX=[O5?D_T./'0VG\BE17V1Y@44 %% !10 44 %36UK/>W,=M:PR3SR
MMM2.-=S,?8"AM+5C2;/>/AY\*8M%:+5]>1)M0&&BMCAD@/J?5OT'OP1ZK7F5
M9\\KGK4:?)&P45F:A10 44 %% !3'59$*NH92,$$<&DTFK,#G]0\-AB9+,A3
MU,;'C\#7%>(O#-MJ\!M=1@:.5,F.0##H?;V_2OD<5AJN6XB.(H_#?3_)EM*I
M'E9Y)KWA#4]"=I'C,]H#Q/$.!_O#M_+WKGZ^[P.,IXRBJM/Y^3['BU:<J<N5
MA1769!10 44 %% '7>%/ASKWBMDEA@^RV)/-W.,*1_LCJWX<>XKWSPEX$T;P
MA /L</FWC#$EW*,R-[#^Z/8?K7'B*M_<B=^&H_;D=317(=H44 %% !10 44
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M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%/_  !$( -(
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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MDA&/,B?JI_0]P17X^?M0?LK^)/V:?%"V]]_Q-/#E\[?V9K42E5E Y\N0?P2
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MX'ZU[I17Z!@_#S*Z&N(E*H_6R^Y:_B8NO)['F=A\"]'@P;NZN[QA_"K"-/R
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MQ7RE>6LEC>36\J[989#$R^ZG!KZYKY^^,F@'2?%'VU%VV]\OF#T\P<,/Z_\
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IHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140019914172216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 19, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 19,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CHROMADEX CORPORATION<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2940963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10900 Wilshire Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Los Angeles<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">90024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(310)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">388-6706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CDXC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001386570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>cdxc-20220519_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cdxc-20220519.xsd" xlink:type="simple"/>
    <context id="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001386570</identifier>
        </entity>
        <period>
            <startDate>2022-05-19</startDate>
            <endDate>2022-05-19</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl80L2ZyYWc6ZjIwZGNlYmQyZTMyNDVjOTg2MmFmNGZmY2E4MmFkOTUvdGFibGU6YmIxNWM5NzEzYmE2NGYyZGI3ZGFkZDBjYWVjZDFkNDMvdGFibGVyYW5nZTpiYjE1Yzk3MTNiYTY0ZjJkYjdkYWRkMGNhZWNkMWQ0M18wLTItMS0xLTg0NDYz_d78bd379-183a-437f-92b1-9ac74ef9e14b">0001386570</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl80L2ZyYWc6ZjIwZGNlYmQyZTMyNDVjOTg2MmFmNGZmY2E4MmFkOTUvdGFibGU6YmIxNWM5NzEzYmE2NGYyZGI3ZGFkZDBjYWVjZDFkNDMvdGFibGVyYW5nZTpiYjE1Yzk3MTNiYTY0ZjJkYjdkYWRkMGNhZWNkMWQ0M18xLTItMS0xLTg0NDYz_b5489db6-c3f7-4b62-a3ca-e5a399162b7c">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8xNjY4_caad9715-cc1c-487f-8110-e1226a812892">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8yMjU_076fcca9-7474-4fa8-9614-f8b93f637fea">2022-05-19</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8xNjY0_a54e1676-9fd7-4c0d-9196-a82dc518a478">CHROMADEX CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGFibGU6NzA5NGYyOTEyMjhhNGU4OTk5NWU0YzA0MDQ2MTBkZTEvdGFibGVyYW5nZTo3MDk0ZjI5MTIyOGE0ZTg5OTk1ZTRjMDQwNDYxMGRlMV8wLTAtMS0xLTg0NDYz_77bd4dc6-f6e8-4135-a529-24349206d521">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGFibGU6NzA5NGYyOTEyMjhhNGU4OTk5NWU0YzA0MDQ2MTBkZTEvdGFibGVyYW5nZTo3MDk0ZjI5MTIyOGE0ZTg5OTk1ZTRjMDQwNDYxMGRlMV8wLTItMS0xLTg0NDYz_97072ed8-cfad-4697-97a0-8a0b4bdaf4e6">001-37752</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGFibGU6NzA5NGYyOTEyMjhhNGU4OTk5NWU0YzA0MDQ2MTBkZTEvdGFibGVyYW5nZTo3MDk0ZjI5MTIyOGE0ZTg5OTk1ZTRjMDQwNDYxMGRlMV8wLTQtMS0xLTg0NDYz_9d51acba-2b8e-4601-9f40-ce75efb95c70">26-2940963</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8xNjY5_d88a605b-abe6-4d04-872e-3dfeb86a3d63">10900 Wilshire Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8xNjY1_d889bd11-9af6-4d65-88fe-bc28d32725be">Suite 600</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8xNjYw_10834414-e915-41a1-808b-9fb4cb956e38">Los Angeles</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8xNjY2_f27e171c-e7ef-4409-b5b7-11e228ec9971">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8xNjcz_285f3ba4-0930-4f85-900a-387298e93779">90024</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8xNjcw_81bb91c4-294b-4033-bb8f-a0f33dcc5365">(310)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8xNjYx_13174e0b-6cc4-483b-9309-60ecbadc5f8e">388-6706</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8xNjYy_fe7736b5-1bad-444a-b371-15f14fe56a42">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8xNjcx_ed4d43f0-6b8d-4da6-8991-8ad8fb0ab34c">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8xNjYz_8ce49bcf-4cbe-4e63-a9d9-b8085fb42972">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8xNjcy_870db41b-65ab-457d-bf4d-912634e0312f">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGFibGU6NjEyZDhiYWZjYTc1NDUzZTgzODUwN2UxOWM3YTdmNDkvdGFibGVyYW5nZTo2MTJkOGJhZmNhNzU0NTNlODM4NTA3ZTE5YzdhN2Y0OV8xLTAtMS0xLTg0NDYz_a8b8eea6-428e-4cc2-a452-daa0251f1ed7">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGFibGU6NjEyZDhiYWZjYTc1NDUzZTgzODUwN2UxOWM3YTdmNDkvdGFibGVyYW5nZTo2MTJkOGJhZmNhNzU0NTNlODM4NTA3ZTE5YzdhN2Y0OV8xLTEtMS0xLTg0NDYz_45085de1-b1df-44c7-9f4a-1b040a8eca73">CDXC</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMTQ2ZGQwN2M0MDQ3OWM5ZmVmMzE4OGVjZDMxOTNmL3NlYzozYzE0NmRkMDdjNDA0NzljOWZlZjMxODhlY2QzMTkzZl8xL2ZyYWc6NDJkNWM5ZGRlNDY1NGJmY2IxMGUxZTJhZTk0ZmM0YTYvdGV4dHJlZ2lvbjo0MmQ1YzlkZGU0NjU0YmZjYjEwZTFlMmFlOTRmYzRhNl8xNjY3_92f8e116-c3ad-48f4-85e5-edd40b61eb8d">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M \ZM]@?6?<?(-#\D+J2!(V?>7,,AGRG[ CQ?2FG>._;<6?S;8/ O4$L#!!0
M   ( "V#LU2?H!OPL0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^
M*T(_8&YB:N*1&+9 8;"-0O-A7Y58=@1Z\62Y<_KKI[-L)VEU9=V'L<VAR=T]
MNKM'=R>9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC
M.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[H
MEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\
M&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>
MV)+;.<V"3J9B+7D%=*RHC_#K3), Z)Q17B@%JXUF X?)8Q1\V .7\@%:^*VZ
MBMU7)/3B4PEM(+#52?2$1C&$"0K$OXP68E^$O?VML*01C\9][/QN]*!_[XSC
M]Y97HA_TOIKS8]$7>'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>
MN77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K
M SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P
M0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC
M=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX
M3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"
ML)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0
MF,7XC&894IT,/O'^8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\ETWLJ
M.?]74_P$4$L#!!0    ( "V#LU27BKL<P    !,"   +    7W)E;',O+G)E
M;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]
M/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^
M0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E
M2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<
M8R6,<6*T_C6"R0_L?@!02P,$%     @ +8.S5*K$(A8S 0  (@(   \   !X
M;"]W;W)K8F]O:RYX;6R-4=%NPC ,_)4J'[ 6M"$-45Y VY"F#8V)]]"ZU"*)
M*\>%C:^?VZH:TE[VE-S9NMQ=%A?BTX'HE'QY%V)N:I%FGJ:QJ,';>$<-!)U4
MQ-Z*0CZFL6&P9:P!Q+MTFF6SU%L,9KD8M;:<W@(2* 0I*-D1>X1+_)UW,#EC
MQ ,ZE._<]'<')O$8T.,5RMQD)HDU75Z(\4I!K-L53,[E9C(,]L""Q1]ZUYG\
MM(?8,V(/'U:-Y&:6J6"%'*7?Z/6M>CR#+@^H%7I")\!K*_#,U#88CIV,IDAO
M8O0]C.=0XIS_4R-5%1:PIJ+U$&3HD<%U!D.LL8DF"=9#;E9T!N[RZ .;<L@F
M:NJF*9ZC#GA3#O9&3R54&*!\4YFHO/93;#GICEYG>O\P>=0>6N=6RKV'5[+E
M&''\GN4/4$L#!!0    ( "V#LU0D'INBK0   /@!   :    >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2
MQ:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/
M:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X\ \PO%WHJ45D
M*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-
MXPFNWPQP>'3^ 5!+ P04    "  M@[-499!YDAD!  #/ P  $P   %M#;VYT
M96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G
M6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y
M2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-F<!B63R-PLQJ
M2AFC-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5
MZ*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(
MRDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X
M>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( "V#LU0'04UB
M@0   +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L!
M A0#%     @ +8.S5/:&V5KN    *P(  !$              ( !KP   &1O
M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ +8.S5)E<G",0!@  G"<  !,
M             ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M"  M@[-4U=+6R3($  !"$   &               @($-"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ +8.S5)^@&_"Q @  X@P   T
M             ( !=0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  M@[-4
MEXJ[',     3 @  "P              @ %1#P  7W)E;',O+G)E;'-02P$"
M% ,4    "  M@[-4JL0B%C,!   B @  #P              @ $Z$   >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ +8.S5"0>FZ*M    ^ $  !H
M         ( !FA$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ +8.S5&60>9(9 0  SP,  !,              ( !?Q(  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  R1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="cdxc-20220519.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chromadex.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="cdxc-20220519.htm">cdxc-20220519.htm</File>
    <File>cdxc-20220519.xsd</File>
    <File>cdxc-20220519_lab.xml</File>
    <File>cdxc-20220519_pre.xml</File>
    <File>chromadexcdxc-jointventure.htm</File>
    <File>chromadexcdxc-pressrelease.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cdxc-20220519.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "cdxc-20220519.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cdxc-20220519_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cdxc-20220519_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cdxc-20220519.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "cdxc",
   "nsuri": "http://chromadex.com/20220519",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdxc-20220519.htm",
      "contextRef": "i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://chromadex.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdxc-20220519.htm",
      "contextRef": "i85ac00a2522a4a2faaac9b394f50bc4f_D20220519-20220519",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chromadex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chromadex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chromadex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chromadex.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chromadex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chromadex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chromadex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chromadex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chromadex.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chromadex.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chromadex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chromadex.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chromadex.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chromadex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chromadex.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chromadex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chromadex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chromadex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chromadex.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chromadex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chromadex.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chromadex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r4": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r5": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001628280-22-014881-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-014881-xbrl.zip
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MI)+,')NZCN%98 1JEB653+GTTN0<V9I4)/PG(2F81WW$-PDYPJ?E&P7^O$?
MS3BYJL$#$=_G&RO+JG]5711X3<'L:I" MS\2C_P0G?^*8HT'?&(H5CO,Z9*T
MPPCM@_$&"@,C878T)#8+HAOB>_SE 1A[Q)+^(IX?($3]!,";,IB]BT5XB=\;
M!"D-631(@A%):.HGWHA_F7T0V;!XF@?4\,546<  ^HD)#4?Y.R\*8'#\#@U*
M'Z-*267- ,5R<'^WOMHL-#VBI/P6^RE@$N-W@S +0B6+YKT=18%- 2TI$,<_
M3YJ.+CQFFEK)-B3%QO21KE/)UDQ%4@Q/T3UFE*BN%G9_^Z5LZOK[!54'_V6
M!N1-0YKTIXI9FX. $5TU,HY(9XM8L79U2S%)]:!)5 V#>L9: DW?9 'TB)1]
M%@6^ Z ++^L@U$"R!6]D/6>_#2^8J[NZYLE2R;: K%U:DJQR69$LZEJ>+5-;
MTYT[R7H"9=++P+Q(TPIPBZ).D?5,0?:8J'60W[SE&UW?0=>G,4-IC9MC^:83
M5,/QB>>AE?M&WS-B^_;"<IA>MAU/TAV;23HK:1(MNV7)MF3+\&Q=+9MWBVV
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M(QBO$)]+8/D)@1F"HXQ N"27<723=M!E[F-2BR;$91X,P?>\BAB_;.3>VUR
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M!/L)B H<+1@[NW#0F9T$U\EB%@_(V>MIN?)$RVV8UA&7I4?Q#8U=Z3B*NOS
M  S6<GOWA>N=UA()G]4 )4@O?-5!MNIDO.H\HHFTUV,TG"J3.(W]:XQD3U'O
M,?R3'7399#S$,J;GLE$D9YSN5H\E8NQ,Y-*B00KLU_/3S-6;FU-NJ8^-SB5%
M&[EW\?UQA>UEBG9LQ8KJ*=;K!S2=+B^8SA+<X8'FT[K/&\&&8B(IP&$"^"R
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M3T1WRZWF/T:5[_ 77L**1"Y])]DAY"]V#58MJ>,A%S2.R3)^>EK>N3]M\1)
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M9C730699!AK=(ZOPVZRQ]KF]U$Z+A[XR24]3(1<TA(@H+(&+! 3(=:5V11D
M[+E$BX_Y)#)^1+,:>&I2.RV?+]3@G *=N=9J9.W76E\*CJPUP^RMQ-:6:B^Q
MU0*-)K8V^%6QM7[>=P;W0\+3[#K-RI6D\DG+T_0FR;/[\K(*(R]D'HJ <$FH
MZU'L%CMK7< Y=Y4,*(?">&.207]3D^9FEK*&N?((\ :YI6Y->#>=YCT8F^-,
M]PXBLL?<KQ$] ^: =\<?>2[8*-GFG+#9:0.W7VS^G<6)]!;Z'M83OKZU%8'/
M 4*>"Y@;0!#Z?N0SHF@0\%Y[+ZJ]3'0H>=A'L'GA%&"=3TG??1<U8DU'C8%T
MC3-6V#/5?\-%&Q/#=UO4HC[/5HNVQ#KW6;0V[BO\+_(B7N493?*/^KM>( F5
MY_M:\\0+ &(< U;\]H9/!>282Q^JT$[S]0XF*O='D$Z!TE;D3T@TU7=_:L:1
MMBDK/03=GOH +3\).+*,V]-I*KBCW>%<&RX"CV!$] T $T0!)$0 J KU6XPC
M%%$5<6:IX)9>)BKC=B\ZOTV'NS8<X-I6=#VG:^]BZB"N#8_BVO#Y71O:N#8<
M(/SBMZ26GR_39+M3@!-=F4,F ?4D LBE'$1AL6':PY['2!1B14SU_C3XU&1>
MXG-*@-9;+!K$[=?S$#J.+&,+)JR$VY5R+[TV@HTFTZXTJNKL;#/0C8MIOT_9
M>7J;Z&H:846%#Q D$""/^8 %2@ /NE&@0NYI0^[EQ8]]3$VB3_VEG#=.,Z?
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M4DX9F^*QQ0.SPYB8?>-QC)BO3,,A%#F^*W3>E6:=9Y$8PBQ%QG.'&.<<66M
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M?HQ&*@OP93+XK\E[D1DM:>W?@,X^9ANKH$R!K-\19HO,E 07JD[H: -UJ"I
M0>+H"^L"XC\/0C6.,020Z!*NA\O9DJ!@#SX.[(*Q) ".M$HIVZG0)?)T> H_
M<3'C?E BK04ZD0WIM$ -HC7'/81;1K8"&XZ3 ,R& F5\C@IH7$XZ')<BTT>^
M.X+WY+ ?2?2;/]!/A;DSDC2#>I6[E-]$_I79Y]M( P\HJTH.6HOG!5\_T"DH
M'TDP!AT#?NN !9>J 1G#>M3##S(@;XB_1'$.LX''PW]E#MM0DR5([_Y [^Z8
M8)N-8\IAZ5=HY.42RM 8-8G3:[""N5Y)HIUI=L.Q#] !R*ND/\'5;,*"I1ZS
MM]PC2:J#C=U-O&<$&M/T7(J9R104Y7 O5M%U7-#'?1HZ6<D<62TP-D*WZ]H8
M&Q] U.TTK\)V4.,\#3;\_#0G,N-@-''NLQ7?EN^ _9:"G""C&8/K.=M^7IA3
M/!WP?S !(WQI[6L8$-)1I;01MX/3C/3-B0D(S3P)" _K4QAMU9^+]P:V.%7J
M[L?+W8:?\X[M(+@4(]:86_;+R)PQC^-B;EF.M$%;E]:96"X\9LU>OQ9[A6V\
MA52NQF2CO%,WK6&TE#W8,?%9=E\QFX*#PB<!O71@O11D;6G,+ Q5H3LU<U7A
M%'MY#"QBPBRLC-V,3>A-D3]+K%OK("/_EE8)"7KC&/O3C_)2AB-QL'&><:$@
MV\?T N!6$^8#P&B1S<)%HQA'B .I@&OG4_:SW,!L&(@ =\G9@M,([X/?KQ7Z
MVC?<& 9QORR$*>D<O?+XB$U#K408F_FK8V06._WX=7UA,_"5"9-[9(BN@6K
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M0*' 6J"L,4F;76_MK[2U15QB'$+D7YM"5["M*30D?F@+7:($U,:&G9"U"II
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M, IS )*8'@P,)8\X(P9O9Y2 ++\WYO8#VQTMVAY/MG>M=+HS@F,=IM%Z[II
M'3V5!.N$*4MBOE%['_'"W[N=W$-LOGZ<F/U*02.;1*C] FTI%K]=2#WXK7;=
MIIWVC'8:-R%"!TA#\R+ZH@;LX4-8>+:%2JVU9ROKP7!)/P^1]4$M:HO6].GV
M\_TO6].:_+',8I$4&FFL*DFC:L3)4C4P^40/$'D*M)A")T%1C6"QX_]=T$%
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MP81=::PSH\ 9^D>P1LX@4$9JLE5F6Y$%_V$]KHE!&2V, \_*PI6Y; *3?<:
M ,#"DHGM1*!M![4,WXY2+LQ 8)(1:=RX@OWII[W!>V@45)BG4B5)Z*56HSF
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M)_15CSS-5!V+0!\9EXY-NR77%0$MD'ZQJ<WSG7EX ,EA*>6!TL_6ZS-?:WF
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M!$NML %\*@"@/1,Q,:D$]>#(/"UZI")NM0L<7BJ7*9<ISPAH/YEXA5\./,;
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M0&:$8(?=9^Q^[.Y0U*_,64WA'GSTP&PU+$Z#SP#4\(,([=.L4-IR'/P2%9R
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MKYUN?>W4]W]@Y/[4Z?1_4$L! A0#%     @ +8.S5"9P WH('@  +;D  !$
M             ( !     &-D>&,M,C R,C U,3DN:'1M4$L! A0#%     @
M+8.S5(Z_W1MJ @  90<  !$              ( !-QX  &-D>&,M,C R,C U
M,3DN>'-D4$L! A0#%     @ +8.S5"T,:%% "@  5%T  !4
M ( !T"   &-D>&,M,C R,C U,3E?;&%B+GAM;%!+ 0(4 Q0    ( "V#LU3%
M5N+@H08  .4P   5              "  4,K  !C9'AC+3(P,C(P-3$Y7W!R
M92YX;6Q02P$"% ,4    "  M@[-4F\85O_8_  ".YP$ '@
M@ $7,@  8VAR;VUA9&5X8V1X8RUJ;VEN='9E;G1U<F4N:'1M4$L! A0#%
M  @ +8.S5'UP&(/.#   134  !X              ( !27(  &-H<F]M861E
L>&-D>&,M<')E<W-R96QE87-E+FAT;5!+!08     !@ & )P!  !3?P     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
